May 01, 2023 4:01 pm EDT Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
Mar 31, 2023 4:01 pm EDT Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 03, 2023 4:01 pm EST Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 01, 2023 4:01 pm EST Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
Feb 21, 2023 4:01 pm EST Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
Feb 08, 2023 4:01 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
Feb 08, 2023 6:00 am EST Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
Feb 06, 2023 8:00 am EST Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
Feb 03, 2023 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2023 4:01 pm EST Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)